Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First‐Line Nonsquamous Non‐Small Cell Lung Cancer

LESSONS LEARNED. The lack of efficacy associated with anti‐EGFL7 combined with standard bevacizumab and chemotherapy in this phase II trial in non‐small cell lung carcinoma is consistent with the lack of benefit observed in colorectal carcinoma, highlighting the challenge of enhancing the efficacy o...

Descripción completa

Detalles Bibliográficos
Autores principales: von Pawel, Joachim, Spigel, David R., Ervin, Thomas, Losonczy, György, Barlesi, Fabrice, Juhász, Erzsébet, Anderson, Maria, McCall, Bruce, Wakshull, Eric, Hegde, Priti, Ye, Weilan, Chen, Daniel, Chang, Ilsung, Rhee, Ina, Reck, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2018
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6067939/
https://www.ncbi.nlm.nih.gov/pubmed/29438092
http://dx.doi.org/10.1634/theoncologist.2017-0690

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6067939/
https://www.ncbi.nlm.nih.gov/pubmed/29438092
http://dx.doi.org/10.1634/theoncologist.2017-0690

Ejemplares similares